This session has been fully organised and funded by Bayer and contains promotional content. Adverse event reporting and prescribing information is available at the end of the presentation.

This presentation will focus on the ‘protect’ and ‘perfect’ elements of the Academic Health Science Network (AHSN) Atrial Fibrillation programme, examining how oral anticoagulation can be optimised for patients with non-valvular atrial fibrillation (NVAF) in line with current guidance, taking into consideration common co-morbidities such as diabetes and renal impairment. It will also explore considerations around dosing and adherence, patient preferences, shared decision-making and the role of structured medication reviews when managing patients with NVAF.

RP-XAR-GB-4124, March 2022